The Journal of Immunology, Vol 154, Issue 7 3525-3537, Copyright © 1995 by American Association of Immunologists

ARTICLES

Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis

LS Davis, AF Kavanaugh, LA Nichols and PE Lipsky
Harold C. Simmons Arthritis Research Center, Dallas, TX.

Rheumatoid arthritis patients undergoing treatment with a murine mAb (BIRR1) to ICAM-1 were studied to determine the effects of the treatment on T cell responsiveness assayed in vitro. Previous studies had demonstrated that over the 5-day treatment period, there was a transient increase in circulating T cells that returned to base line 3 days after therapy. The transient lymphocytosis correlated with a loss in delayed-type hypersensitivity reactivity during the time of Ab administration. However, neither the increase in T cell numbers nor the inhibition of delayed-type hypersensitivity responses correlated with the immediate clinical benefit of therapy or the prolonged nature of the response to therapy in some patients. The current studies show that after the return of lymphocyte numbers to pretreatment levels, a decrease in T lymphocyte responses to suboptimal activation signals, including accessory cell-dependent (low dose PHA and soluble anti-CD3 mAb) and accessory cell-independent stimuli (immobilized anti-CD3 mAb), was observed. However, responses to recall Ags were preserved. Depressed T cell responses were not the result of diminished accessory cell function or production of suppressive factors by monocytes, but rather reflected decreased IL-2 production. The duration of T cell hyporesponsiveness was variable in length but lasted up to 5 mo after treatment with anti-ICAM-1 mAb. The induction and persistence of T cell hyporesponsiveness correlated with an improvement in disease activity in treated patients. These studies show that treatment with anti-ICAM-1 mAb can induce T cell hyporesponsiveness that correlates with and may explain sustained therapeutic benefit in patients with rheumatoid arthritis.

This article has been cited by other articles:

				B R Yacyshyn, W Y Chey, J Goff, B Salzberg, R Baerg, A L Buchman, J Tami, R Yu, E Gibiansky, and W R Shanahan Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease Gut, July 1, 2002; 51(1): 30 - 36. [Abstract] [Full Text] [PDF]

				A. Hamann and U. Syrbe T-cell trafficking into sites of inflammation Rheumatology, July 1, 2000; 39(7): 696 - 699. [Full Text] [PDF]

				S. Yoshida, T. Katoh, T. Tetsuka, K. Uno, N. Matsui, and T. Okamoto Involvement of Thioredoxin in Rheumatoid Arthritis: Its Costimulatory Roles in the TNF-{alpha}-Induced Production of IL-6 and IL-8 from Cultured Synovial Fibroblasts J. Immunol., July 1, 1999; 163(1): 351 - 358. [Abstract] [Full Text] [PDF]

				M. Makino, M. Azuma, S.-I. Wakamatsu, Y. Suruga, S. Izumo, M. M. Yokoyama, and M. Baba Marked Suppression of T Cells by a Benzothiophene Derivative in Patients with Human T-Lymphotropic Virus Type I-Associated Myelopathy/Tropical Spastic Paraparesis Clin. Vaccine Immunol., May 1, 1999; 6(3): 316 - 322. [Abstract] [Full Text] [PDF]

				R. Brey, A. Amato, K. Kagan-Hallet, C. Rhine, and C. Stallworth Anti-Intercellular Adhesion Molecule-1 (ICAM-1) antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice Lupus, January 1, 1997; 6(8): 645 - 651. [Abstract] [PDF]